Tyra Biosciences, Inc. Share Price
TYRATyra Biosciences, Inc. Stock Performance
Open $34.27 | Prev. Close $33.76 | Circuit Range N/A |
Day Range $34.12 - $35.27 | Year Range $8.75 - $40.42 | Volume 35,265 |
Average Traded $34.72 |
Tyra Biosciences, Inc. Share Price Chart
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Tyra Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
30-Apr-26 | $34.27 | $34.72 | +0.00% |
30-Apr-26 | $34.27 | $34.72 | -0.81% |
28-Apr-26 | $37.99 | $35.00 | -5.20% |
27-Apr-26 | $38.27 | $36.92 | -1.86% |
24-Apr-26 | $36.62 | $37.62 | +2.51% |
23-Apr-26 | $37.52 | $36.70 | -1.91% |
22-Apr-26 | $37.94 | $37.41 | +2.06% |